RedoxTherapies, Juno Therapeutics deal

Juno acquired fellow cancer company RedoxTherapies. RedoxTherapies will receive $10 million in cash up front and is eligible for undisclosed milestones. The deal gives Juno vipadenant ( V2006), a small molecule adenosine A2A receptor (ADORA2A) antagonist. Juno said vipadenant may disrupt immunosuppressive pathways in the tumor microenvironment. The company plans to study vipadenant in combination with its engineered T cells. ...